Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Featured | Mon 08, 2024
Featured Article about the Priority Access Program on Startupticker
A new article about Bottneuro's Priority Access Program has just been published on Startupticker, Switzerland's leading platform for startup news and
Business Update | Wed 05, 2024
Priority Access Program
As part of our Priority Access Program, we are offering neurology clinics in Switzerland up to 25 Miamind® devices for young people with mild and mode
Business Update | Mon 04, 2024
Advancing Neurological Care Across the EU with Bottneuro GmbH
Join Us in Advancing Neurological Care Across the EU with Bottneuro GmbH
Events & Conferences | Mon 04, 2024
Bottneuro at the Mental & Brain Tech Tour 2024
Bottneuro has been chosen as one of the top 32 companies to present at the Mental & Brain Tech Tour 2024!
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
